Physiopathologie, autoimmunité, maladies neuromusculaire et thérapie régénératrice
- Research works
- 21 ▲ 123% vs 2013–17
- Citations
- 477 23.2 per fractional work
- Top-10% rate
- 19.4% record average 16.5%
- Open access
- 59% world 28%
Not ranked overall: Physiopathologie, autoimmunité, maladies neuromusculaire et thérapie régénératrice is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 9.3×. Every wedge is a field page.
Which keywords describe research at Physiopathologie, autoimmunité, maladies neuromusculaire et thérapie régénératrice?
By fractional works in all years, weighted toward what it does more of than the world: Autoantibodies, Diagnosis, Epidemiology, Treatment, Autoimmune, Inflammation, Immunosuppressive Therapy and Rituximab.
- Management
- Rituximab
- Autoimmune
- Treatment
- Epidemiology
- Autoantibodies
- Diagnosis
- Inflammation
- Immunosuppressive Therapy
- Quality of Life
- Intravenous Immunoglobulin
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 11 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 11 words, with their numbers
- Autoantibodies4▲ 73×7 topics
- Epidemiology3▲ 3.9×28 topics
- Diagnosis3▲ 14×11 topics
- Treatment2▲ 8.0×15 topics
- Inflammation2▲ 4.2×19 topics
- Autoimmune2▲ 178×2 topics
- Immunosuppressive Therapy1▲ 36×5 topics
- Rituximab1▲ 40×4 topics
- Quality of Life1▲ 4.3×6 topics
- Management1▲ 7.2×5 topics
- Intravenous Immunoglobulin1▲ 81×3 topics
Which research topics does Physiopathologie, autoimmunité, maladies neuromusculaire et thérapie régénératrice publish most on?
By volume in 2022–2025: Autoimmune Bullous Skin Diseases, Renal Transplantation Outcomes and Treatments, Transgenic Plants and Applications and CAR-T cell therapy research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Autoimmune Bullous Skin Diseases Pathology and Forensic Medicine 1 works
- 2 Renal Transplantation Outcomes and Treatments Transplantation 0 works
- 3 Transgenic Plants and Applications Biotechnology 0 works
- 4 CAR-T cell therapy research Oncology 0 works
- 5 Health, Education, and Cultural Studies Sociology and Political Science 0 works
- 6 Drug-Induced Adverse Reactions Pharmacology 0 works
- 7 Inflammatory Myopathies and Dermatomyositis Epidemiology 0 works
- 8 Urticaria and Related Conditions Rheumatology 0 works
- 9 Complement system in diseases Immunology 0 works
- 10 Renal and Vascular Pathologies Pulmonary and Respiratory Medicine 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Physiopathologie, autoimmunité, maladies neuromusculaire et thérapie régénératrice's research output changed?
Output in 2018–2022 was 123% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Rouen
- Centre Henri Becquerel
- Normandie Innovation Marché Entreprise Consommation
- Laboratoire d'Analyse des Sociétés, Transformations et Adaptations
- Génomique du cancer et du cerveau
- Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau
- Neuroendocrine, Endocrine and Germinal Differentiation Communication
- Laboratoire Sciences et Méthodes Séparatives
- Laboratoire d'économie Rouen Normandie
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.